Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.
about
Small molecule inhibitors of zinc-dependent histone deacetylasesLysine deacetylase (KDAC) regulatory pathways: an alternative approach to selective modulationEmerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series)Acetyl-lysine erasers and readers in the control of pulmonary hypertension and right ventricular hypertrophyA selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related testsExploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation AssaysVirtual screening and experimental validation of novel histone deacetylase inhibitorsLight-controlled modulation of gene expression by chemical optoepigenetic probesDiscovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activitySynthesis and biological evaluation of largazole analogues with modified surface recognition cap groupsFDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors.Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation.Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition EnhancersComputational design of a time-dependent histone deacetylase 2 selective inhibitor.The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cellsGITR subverts Foxp3(+) Tregs to boost Th9 immunity through regulation of histone acetylationSignal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy.Isoform-selective histone deacetylase inhibitorsComputational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors.Histone deacetylase inhibitors (HDACIs). Structure--activity relationships: history and new QSAR perspectives.Mutagenesis studies of the 14 Å internal cavity of histone deacetylase 1: insights toward the acetate-escape hypothesis and selective inhibitor design.Pharmacological inhibition of histone deacetylases for the treatment of cancer, neurodegenerative disorders and inflammatory diseases.Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia.Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications.Epigenetic molecular recognition: a biomolecular modeling perspective.Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.The effect of various zinc binding groups on inhibition of histone deacetylases 1-11.Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor.Class I HDAC inhibition stimulates cardiac protein SUMOylation through a post-translational mechanism.Structure-activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery.Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.New 5-Aryl-Substituted 2-Aminobenzamide-Type HDAC Inhibitors with a Diketopiperazine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death.Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor.Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts.A salt bridge turns off the foot-pocket in class-II HDACs.Computer- and Structure-Based Lead Identification for Epigenetic Targets
P2860
Q26824515-4CD4AA5F-6ED6-449B-ACFF-E5400C7EFA58Q27021965-092D3004-F668-4497-930D-0E068A8885E0Q28082797-08424939-E841-411C-AFF4-B43EA236A592Q28084598-BD53229A-B1F7-404C-BD5A-1167642CC46BQ28535325-5ADE3131-96BA-4734-BBC0-605312787F11Q28550025-62B26874-CE56-4781-BD1F-6AE6C2915C7AQ28829470-1BB39806-C9C2-493B-A549-4A008CB64067Q28834530-3B7B7629-3361-41A2-9BB4-B7425169D8C3Q33649465-ECE84A68-1FC0-417A-B018-2BC314DD817CQ34302247-0EF77200-1CCB-4080-B0A9-8D63EFBCCD07Q34354229-BB4F4A16-51C6-4DE9-BEF1-80DBC567054AQ34739990-96615817-BBE5-46DD-AFC4-10287C98447EQ35025021-858992AE-6228-4C78-B644-4D0050EAB641Q35213063-BD84AE22-BED4-4207-889F-7A671447570BQ35556954-FF1D403F-B9C5-4E2D-B747-9684D878F524Q36060837-1A6D0BD6-06D6-4AEF-BB6F-B126C298040EQ36932490-9F437D50-5226-4B84-920B-D7B52F4D06BAQ36995048-A2B356C1-8589-43BC-AFA1-573DC891A525Q37397325-B2307711-05AD-474A-918A-6F13160CC320Q37693855-EE160045-4DA2-40F3-BCC1-3023EAC6A13CQ37697360-68DF6EA2-4375-432F-8E2B-18A433FA0945Q38090679-8C2884D6-CF75-4E59-BD9A-ACECAE4546A6Q38136307-F9EAEEE0-BB1A-48D4-A95B-9FFC3DEB4E99Q38162900-D4E430AE-3996-4B84-95DB-F2CDD7A7D740Q38195005-C7858D12-E929-494B-8440-85D5310420A8Q38204386-013E23CC-7FCF-4E4C-934B-CAE15B223D1BQ38703315-47E2AD00-9153-437D-98FB-1B6AEB627994Q39283136-35F13540-CDD4-415D-903B-FDF55E41D28BQ39785574-27AA3388-84FD-4BE8-81EC-156B58AEA7D0Q43051844-2AE62051-F928-4BFD-BBAB-41ED2B2ABC64Q47357144-D2BE7200-2BBF-43C6-B80F-4FDC57C326BDQ47614980-A7B9B7A4-C02D-4D44-A881-524301CEFB5AQ48181021-E8B89AA0-1D43-474D-A7F1-28CD55B036ABQ50862788-93BE7002-2FBB-4BD1-B1F6-A8CAF6122694Q51054177-76A7782B-4D4E-4904-8E71-07DD83E106D7Q51740044-5C44C923-572F-48C8-85A8-8F544AAC0956Q52729300-131997B5-762C-4C23-B114-2C42FDC6D786Q52793543-4F764011-51F4-4F1B-8F00-42AF2DC87870Q53060196-E801BCA9-B82A-48D6-A822-0F8C1108F85FQ58860105-3A700BEB-8F28-4EDC-ADA2-28FB772D98AE
P2860
Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Novel aminophenyl benzamide-ty ...... anced potency and selectivity.
@en
type
label
Novel aminophenyl benzamide-ty ...... anced potency and selectivity.
@en
prefLabel
Novel aminophenyl benzamide-ty ...... anced potency and selectivity.
@en
P2093
P356
P1476
Novel aminophenyl benzamide-ty ...... anced potency and selectivity.
@en
P2093
Arkadii F Vaisburg
Claire Bonfils
Isabelle Paquin
James Wang
Jeffrey M Besterman
Jianhong Liu
Jubrail Rahil
Marie-Claude Trachy-Bourget
Marielle Fournel
P304
P356
10.1021/JM701079H
P407
P577
2007-10-17T00:00:00Z